p300 expression is related to high-risk human papillomavirus infections and severity of cervical intraepithelial neoplasia but not to viral or disease outcomes in a longitudinal setting

dc.contributor.authorSyrjänen, Stinapor
dc.contributor.authorNaud, Paulopor
dc.contributor.authorSarian, Luispor
dc.contributor.authorDerchain, Sophiepor
dc.contributor.authorRoteli-Martins, Ceciliapor
dc.contributor.authorLongatto, Adhemarpor
dc.contributor.authorTatti, Silviopor
dc.contributor.authorBranca, Margheritapor
dc.contributor.authorErzen, Mojcapor
dc.contributor.authorSerpa-Hammes, Lucianopor
dc.contributor.other[et al.]
dc.date.accessioned2020-10-19T09:35:14Z
dc.date.embargo10000-01-01
dc.date.issued2010-03
dc.description.abstractTo evaluate the role of the expression of the transcription factor p300 as an independent predictor of high-risk human papillomavirus (HR-HPV) infections and outcome of the cervical disease.Cervical biopsy samples taken at enrolment from 225 women of the Latin American Screening study cohort were analyzed for p300 using immunohistochemistry to assess its value as predictor of (a) cervical intraepithelial neoplasia (CIN) grade, and (b) HR-HPV at baseline, as well as (c) outcomes of HR-HPV infections, and (d) development of incident CIN as surrogate endpoints of progressive disease.There was a significant linear trend in increasing upregulation (=pattern shift) of p300 (P=0.0001) in parallel with increasing grade of CIN. When dichotomized (normal/moderately increase vs. strong-intense), upregulated p300 expression predicted CIN3+ with odds ratio=4.16 (95% confidence interval: 1.95-8.86) (P=0.0001) and CIN2+ with odds ratio=3.48 (95% confidence interval: 1.86-6.48) (P=0.0001). p300 was upregulated more often in HR-HPV+ lesions than in those remaining negative. Semiquantitative viral loads were also directly related to upregulation of p300 (P=0.036), but p300 was not a significant predictor of disease progression to either CIN1+ or CIN2+.p300 expression was upregulated in CIN lesions and related to detection and viral load of HR-HPV but not to their outcome or to incident CIN.por
dc.description.sponsorshipThis study has been supported by the European Commission, INCO-DEV Programme (Contract ICA4-CT-2001-10013).por
dc.distributioninternationalpor
dc.identifier.doi10.1097/PGP.0b013e3181bccaecpor
dc.identifier.eissn1538-7151
dc.identifier.issn0277-1691
dc.identifier.pmid20173499por
dc.identifier.urihttps://hdl.handle.net/1822/67564
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherLippincott, Williams & Wilkinspor
dc.relationICA4-CT-2001-10013por
dc.rightsclosedAccesspor
dc.subjectBiomarkers, Tumorpor
dc.subjectBiopsypor
dc.subjectCervical Intraepithelial Neoplasiapor
dc.subjectCohort Studiespor
dc.subjectDNA, Viralpor
dc.subjectE1A-Associated p300 Proteinpor
dc.subjectFemalepor
dc.subjectHumanspor
dc.subjectImmunohistochemistrypor
dc.subjectLongitudinal Studiespor
dc.subjectPapillomaviridaepor
dc.subjectPapillomavirus Infectionspor
dc.subjectProspective Studiespor
dc.subjectStatistics, Nonparametricpor
dc.subjectp300por
dc.subjectHR-HPVpor
dc.subjectCervical cancerpor
dc.subjectLongitudinal predictive valuespor
dc.subjectSurrogate endpointspor
dc.subjectCINpor
dc.subject.wosScience & Technologypor
dc.titlep300 expression is related to high-risk human papillomavirus infections and severity of cervical intraepithelial neoplasia but not to viral or disease outcomes in a longitudinal settingpor
dc.typearticlepor
dspace.entity.typePublicationen
oaire.citationEndPage145por
oaire.citationIssue2por
oaire.citationStartPage135por
oaire.citationVolume29por
sdum.journalInternational Journal of Gynecological Pathologypor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
10.1097@PGP.0b013e3181bccaec.pdf
Tamanho:
366.5 KB
Formato:
Adobe Portable Document Format